Title : Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.

Pub. Date : 2020 Jun 1

PMID : 31911548






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Nineteen percent (5/27) of patients treated with first-line osimertinib had off-target genetic resistance (2 MET amplification, 1 KRAS mutation, 1 RET fusion, and 1 BRAF fusion) whereas 4% (1/27) had an acquired EGFR mutation (EGFR G724S). osimertinib ret proto-oncogene Homo sapiens